IDEXX Laboratories Reports Strong Q4 & FY2025 Results, Provides Positive 2026 Outlook

summarizeSummary

IDEXX Laboratories delivered a strong close to 2025, demonstrating robust operational execution, particularly within its Companion Animal Group. The significant growth in capital instrument revenues, driven by record placements of key diagnostic platforms like IDEXX inVue Dx, highlights successful innovation and market penetration. The company's positive outlook for 2026, including solid revenue and EPS growth projections, suggests continued momentum and confidence in its strategic initiatives. Investors will likely view these results and guidance favorably, reinforcing the company's position as a leader in pet healthcare innovation.

check_boxKey Events

• Strong Q4 2025 Performance

  Achieved 14% reported revenue growth and 18% reported EPS growth for the fourth quarter of 2025, exceeding prior year results.

• Record Instrument Placements

  Reported a 76% increase in CAG Diagnostics capital instrument revenues, including over 1,900 IDEXX inVue Dx placements, contributing to a 12% year-over-year expansion of the global premium instrument installed base.

• Positive 2026 Financial Outlook

  Provided initial 2026 guidance projecting 7.0% - 9.0% organic revenue growth and 10% - 14% comparable EPS growth, indicating continued strong performance expectations.

auto_awesomeAnalysis

IDEXX Laboratories delivered a strong close to 2025, demonstrating robust operational execution, particularly within its Companion Animal Group. The significant growth in capital instrument revenues, driven by record placements of key diagnostic platforms like IDEXX inVue Dx, highlights successful innovation and market penetration. The company's positive outlook for 2026, including solid revenue and EPS growth projections, suggests continued momentum and confidence in its strategic initiatives. Investors will likely view these results and guidance favorably, reinforcing the company's position as a leader in pet healthcare innovation.